DSM265   Click here for help

GtoPdb Ligand ID: 9644

PDB Ligand Antimalarial Ligand
Compound class: Synthetic organic
Comment: DSM265 is an optimised candidate and clinical lead from the triazolopyrimidine structural class and represents a new class of antimalarial drug [1].

The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 55.11
Molecular weight 415.07
XLogP 4.9
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES Cc1cc(Nc2ccc(cc2)S(F)(F)(F)(F)F)n2c(n1)nc(n2)C(F)(F)C
Isomeric SMILES Cc1cc(Nc2ccc(cc2)S(F)(F)(F)(F)F)n2c(n1)nc(n2)C(F)(F)C
InChI InChI=1S/C14H12F7N5S/c1-8-7-11(26-13(22-8)24-12(25-26)14(2,15)16)23-9-3-5-10(6-4-9)27(17,18,19,20)21/h3-7,23H,1-2H3
No information available.
Summary of Clinical Use Click here for help
DSM265 has completed a Phase 2a clinical trial (NCT02123290) for single-dose treatment of malaria caused by P. falciparum and P. vivax infection. Results from this trial demonstrate rapid clearance of P. falciparum parasitaemia but less effective clearance kinetics for P. vivax [3]. Extended observation identified a resistance-associated mutation in PfDHODH in a number of individuals with recurrence of P. falciparum malaria, leading to the recommendation that further clinical development takes this into consideration to safeguard the therapeutic potential of DSM265.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02123290 DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax Phase 2 Interventional Medicines for Malaria Venture 3
Pharmacokinetics Click here for help
The terminal half-life for elimination is 86 to 118 hours [4].